RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthmaDavid Lamb(Boehringer Ingelheim (Germany)), Denis Delić(Boehringer Ingelheim (Germany))Respiratory ResearchMay 22, 202110.1186/s12931-021-01743-7Cited by 24SaveCiteExport RISWatch citationsRelated PapersInhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells|Oncotarget|2020|9